EA201600012A1 - Способ профилактики и/или лечения сердечно-сосудистых заболеваний - Google Patents

Способ профилактики и/или лечения сердечно-сосудистых заболеваний

Info

Publication number
EA201600012A1
EA201600012A1 EA201600012A EA201600012A EA201600012A1 EA 201600012 A1 EA201600012 A1 EA 201600012A1 EA 201600012 A EA201600012 A EA 201600012A EA 201600012 A EA201600012 A EA 201600012A EA 201600012 A1 EA201600012 A1 EA 201600012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
cardiovascular diseases
statin
acetylsalicylic acid
Prior art date
Application number
EA201600012A
Other languages
English (en)
Other versions
EA028969B1 (ru
Inventor
Пабло Мартин Санс
Хавьер Урбано Уртадо
Original Assignee
Феррер Интернасионал, С.А.
Фундасион Сентро Насионал де Инвестигасионес Кардиоваскуларес Карлос III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Феррер Интернасионал, С.А., Фундасион Сентро Насионал де Инвестигасионес Кардиоваскуларес Карлос III filed Critical Феррер Интернасионал, С.А.
Publication of EA201600012A1 publication Critical patent/EA201600012A1/ru
Publication of EA028969B1 publication Critical patent/EA028969B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к фармацевтическому составу, включающему ингибитор редуктазы ГМГ-КоА, в частности статин, и ацетилсалициловую кислоту таким образом, чтобы минимизировать взаимодействие ацетилсалициловой кислоты со статином, для профилактики или лечения сердечно-сосудистых заболеваний.
EA201600012A 2013-06-06 2014-06-05 Способ профилактики и/или лечения сердечно-сосудистых заболеваний EA028969B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases
PCT/EP2014/061735 WO2014195421A1 (en) 2013-06-06 2014-06-05 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
EA201600012A1 true EA201600012A1 (ru) 2016-07-29
EA028969B1 EA028969B1 (ru) 2018-01-31

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600012A EA028969B1 (ru) 2013-06-06 2014-06-05 Способ профилактики и/или лечения сердечно-сосудистых заболеваний

Country Status (42)

Country Link
US (1) US10617699B2 (ru)
EP (3) EP2810644A1 (ru)
JP (1) JP6151854B2 (ru)
KR (1) KR101839665B1 (ru)
CN (2) CN104224804A (ru)
AP (1) AP2015008882A0 (ru)
AR (1) AR096350A1 (ru)
AU (1) AU2014276883B2 (ru)
BR (1) BR112015030350B1 (ru)
CA (1) CA2912350C (ru)
CL (1) CL2015003561A1 (ru)
CR (1) CR20150635A (ru)
CU (1) CU24326B1 (ru)
CY (1) CY1118766T1 (ru)
DK (1) DK2986281T3 (ru)
DO (1) DOP2015000296A (ru)
EA (1) EA028969B1 (ru)
EC (1) ECSP15050273A (ru)
ES (1) ES2620078T3 (ru)
GE (1) GEP201706743B (ru)
HK (1) HK1204562A1 (ru)
HU (1) HUE033458T2 (ru)
IL (1) IL242569B (ru)
MA (1) MA38699B1 (ru)
MD (1) MD4475C1 (ru)
MX (1) MX347801B (ru)
MY (1) MY181272A (ru)
NI (1) NI201500171A (ru)
NZ (1) NZ714707A (ru)
PE (1) PE20160051A1 (ru)
PH (1) PH12015502706B1 (ru)
PL (1) PL2986281T3 (ru)
PT (1) PT2986281T (ru)
RS (1) RS55786B1 (ru)
SA (1) SA515370243B1 (ru)
SG (1) SG11201509353QA (ru)
SI (1) SI2986281T1 (ru)
TN (1) TN2015000501A1 (ru)
TW (1) TWI630928B (ru)
UA (1) UA113806C2 (ru)
WO (1) WO2014195421A1 (ru)
ZA (1) ZA201508452B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530292B (zh) * 2015-04-16 2022-11-01 诺华股份有限公司 瑞博西尼片剂
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
PL4299063T3 (pl) * 2022-06-30 2024-06-10 Ferrer Internacional, S.A. Kapsułki doustne zawierające tabletki atorwastatyny wykazujące odpowiedni profil rozpuszczania i biodostępność
MX2024011227A (es) 2024-09-12 2026-04-01 Laboratorios Silanes S A De C V Composicion farmaceutica que comprende rosuvastatina y acido acetilsalicilico, proceso de preparacion y usos de la misma

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
CN1216596C (zh) 2000-02-10 2005-08-31 Bpsi控股公司 丙烯酸肠溶性涂层组合物
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
EP1648422A4 (en) 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
US8277844B2 (en) 2003-08-20 2012-10-02 Shionogi & Co., Ltd. Coating composition
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
US20090098201A1 (en) * 2004-06-28 2009-04-16 Bio Intellectual Property Services (Bio Ips) Llc Composition and Method for Treatment and Prevention of Atherosclerosis
US20080176947A1 (en) 2005-03-11 2008-07-24 Peter Herold Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
KR100955669B1 (ko) 2007-08-13 2010-05-06 한올바이오파마주식회사 ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
DK2273985T3 (en) * 2008-03-28 2016-04-25 Ferrer Int Capsule for the prevention of cardiovascular diseases
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (en) * 2009-04-30 2012-11-07 Reddys Lab Ltd Dr MEDICINAL COMBINATION FORMULATIONS WITH DETERMINED DOSAGE
CA2777455A1 (en) 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Novel 1,3-oxazolidine compounds and their use as renin inhibitors
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
AU2014276883B2 (en) 2017-04-20
ES2620078T3 (es) 2017-06-27
AU2014276883A1 (en) 2015-11-26
CR20150635A (es) 2016-06-10
CU20150173A7 (es) 2016-06-29
JP2016520135A (ja) 2016-07-11
PH12015502706A1 (en) 2016-03-14
AP2015008882A0 (en) 2015-11-30
WO2014195421A1 (en) 2014-12-11
RS55786B1 (sr) 2017-07-31
AR096350A1 (es) 2015-12-23
MD4475B1 (ru) 2017-04-30
CU24326B1 (es) 2018-03-13
TN2015000501A1 (en) 2017-04-06
HK1204562A1 (en) 2015-11-27
CA2912350A1 (en) 2014-12-11
GEP201706743B (en) 2017-09-25
CA2912350C (en) 2017-04-04
MX2015015753A (es) 2016-08-03
DK2986281T3 (en) 2017-04-03
MX347801B (es) 2017-05-15
DOP2015000296A (es) 2016-12-30
SA515370243B1 (ar) 2016-09-19
EP2810644A1 (en) 2014-12-10
US10617699B2 (en) 2020-04-14
PH12015502706B1 (en) 2016-03-14
KR20160014622A (ko) 2016-02-11
SG11201509353QA (en) 2015-12-30
ZA201508452B (en) 2017-02-22
MD4475C1 (ru) 2017-11-30
PT2986281T (pt) 2017-03-29
CL2015003561A1 (es) 2016-06-10
CN104224804A (zh) 2014-12-24
MA38699B1 (fr) 2017-09-29
HUE033458T2 (en) 2017-12-28
BR112015030350B1 (pt) 2022-11-29
EP2986281B1 (en) 2016-12-21
PE20160051A1 (es) 2016-01-25
KR101839665B1 (ko) 2018-03-16
TWI630928B (zh) 2018-08-01
NI201500171A (es) 2019-05-07
BR112015030350A2 (pt) 2017-07-25
PL2986281T3 (pl) 2017-06-30
JP6151854B2 (ja) 2017-06-21
SI2986281T1 (sl) 2017-07-31
TW201536357A (zh) 2015-10-01
CN113143888A (zh) 2021-07-23
NZ714707A (en) 2019-04-26
EP3175849A1 (en) 2017-06-07
CY1118766T1 (el) 2017-07-12
IL242569B (en) 2018-12-31
EA028969B1 (ru) 2018-01-31
ECSP15050273A (es) 2017-07-31
UA113806C2 (xx) 2017-03-10
MA38699A1 (fr) 2017-01-31
MY181272A (en) 2020-12-21
EP2986281A1 (en) 2016-02-24
MD20160001A2 (ru) 2016-05-31
US20160106763A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
EA201490688A1 (ru) 2-тиопиримидиноны
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX373320B (es) Compuestos inhibidores de pde2.
EP2557919A4 (en) STABILIZED FORMULATIONS OF STATIN
PE20142182A1 (es) Inhibidores de iap
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
MX2017012132A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
MX2017002541A (es) Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa.
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
EA201792093A1 (ru) 2-тиопиримидиноны
SG11201801382UA (en) PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND AN ACE INHIBITOR
MX388159B (es) Estatina para la prevención/reducción de daño relacionado con isquemia
LV14963A (lv) Endoteliālās disfunkcijas korektors
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита